Corporate News Report
Novabridge Biosciences (NBP) advanced 3.01 % during the 24‑hour window that concluded at 02:27 PM Central Europe on Monday, 26 May 2026. The share, currently priced at USD 1.37 on major exchanges, trades against a supply of 116 million shares and a market capitalization of USD 158.9 million. In the last 24 hours, the company saw a trade volume of approximately USD 765 k. Compared with the close at the end of the previous month, NBP’s price has declined 5.52 %.
Key technical indicators for NBP are as follows:
- Simple moving average (200 days): USD 2.25
- 52‑week high: USD 5.19 (recorded on 01 June 2026)
- 52‑week low: USD 1.26 (recorded on 22 October 2026)
Recent Scientific Update
Novabridge Biosciences announced that the latest Phase 1b data for its CLDN18.2‑targeted bispecific antibody, givastomig, presented at the European Society for Medical Oncology Congress in Madrid, supports progression to a planned Phase 3 study. The analysis, covering 71 patients through early August 2026, provides nearly 18 months of median follow‑up for the 8 mg/kg cohort— the dose selected for registrational development.
Key efficacy findings for the 8 mg/kg cohort include:
- Objective response rates approaching 80 %
- Disease control rates exceeding 95 %
- Median response duration just over 15 months
- Progression‑free survival close to 17 months
Safety data remained manageable, with no high‑grade events attributable to givastomig and only mild gastritis reported. The company has secured FDA alignment on a global registrational protocol and holds both Orphan Drug and Fast‑Track designations, underscoring a clear regulatory pathway for the program.
Related Stock Performance (Last 24 Hours)
| Symbol | Movement | Current Price (USD) | Market Cap (USD mn) |
|---|---|---|---|
| INGN | +0.85 % | 7.10 | 188.4 |
| FIRY | –1.64 % | 11.43 | 190 |
| RNAC | –3.59 % | 6.18 | 187 |
| PNNT | –0.69 % | 2.87 | 187.4 |
| ELDN | 0 % | 2.30 | 187.1 |
The performance of these peers provides context for NBP’s recent movement, indicating a broader sector trend and highlighting the competitive landscape in which Novabridge operates.
Company Overview
Novabridge Biosciences, formerly known as I‑Mab Biopharma, is a clinical‑stage biopharmaceutical enterprise headquartered in Shanghai, China. The company focuses on discovering, developing, and commercializing novel biologics that address significant unmet medical needs, particularly in oncology and autoimmune disease. Operating within the healthcare sector, Novabridge aims to translate early‑stage discoveries into transformative therapies for patients worldwide.
